Advances in genetic sequencing technology are accelerating our understanding of the molecular changes that lead to blood cancers. This includes analyzing genetic alterations linked to these diseases so doctors can match patients with the best treatments, exploring the potential of hematopoietic stem cells, and investigating epigenetic approaches to understanding and treating these malignancies.
Pictured: Richard O’Reilly, Chief of the Pediatric Bone Marrow Transplant Service, with a patient. Dr. O’Reilly is studying the immunology of stem-cell transplants and developing new cell-based therapies for children with blood disorders.
